These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 36309224)

  • 1. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
    Najafi S; Majidpoor J; Mortezaee K
    Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulatory effects of gut microbiome in cancer immunotherapy: A novel paradigm for blockade of immune checkpoint inhibitors.
    Rezasoltani S; Yadegar A; Asadzadeh Aghdaei H; Reza Zali M
    Cancer Med; 2021 Feb; 10(3):1141-1154. PubMed ID: 33369247
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy.
    Huang J; Liu D; Wang Y; Liu L; Li J; Yuan J; Jiang Z; Jiang Z; Hsiao WW; Liu H; Khan I; Xie Y; Wu J; Xie Y; Zhang Y; Fu Y; Liao J; Wang W; Lai H; Shi A; Cai J; Luo L; Li R; Yao X; Fan X; Wu Q; Liu Z; Yan P; Lu J; Yang M; Wang L; Cao Y; Wei H; Leung EL
    Gut; 2022 Apr; 71(4):734-745. PubMed ID: 34006584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy.
    Wang Y; Ma R; Liu F; Lee SA; Zhang L
    Front Immunol; 2018; 9():374. PubMed ID: 29556232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.
    Ren S; Feng L; Liu H; Mao Y; Yu Z
    Thorac Cancer; 2024 May; 15(14):1149-1163. PubMed ID: 38572783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluctuations in Gut Microbiome Composition During Immune Checkpoint Inhibitor Therapy.
    Sarkar J; Cortes Gomez E; Oba T; Chen H; Dy GK; Segal BH; Ernstoff MS; Ito F
    World J Oncol; 2023 Jun; 14(3):178-187. PubMed ID: 37350807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the relationship between intestinal microbiota and immune checkpoint inhibitors in the treatment of non-small cell lung cancer: insights from the "lung and large intestine stand in exterior-interior relationship" theory.
    Li L; Zhong H; Wang Y; Pan Z; Xu S; Li S; Zeng G; Zhang W; Li J; He L
    Front Cell Infect Microbiol; 2024; 14():1341032. PubMed ID: 38415012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-1/PD-L1 blockade: Prospectives for immunotherapy in cancer and autoimmunity.
    Hosseinzadeh R; Feizisani F; Shomali N; Abdelbasset WK; Hemmatzadeh M; Gholizadeh Navashenaq J; Jadidi-Niaragh F; Bokov DO; Janebifam M; Mohammadi H
    IUBMB Life; 2021 Nov; 73(11):1293-1306. PubMed ID: 34538007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome.
    Zou R; Wang Y; Ye F; Zhang X; Wang M; Cui S
    Clin Transl Oncol; 2021 Nov; 23(11):2237-2252. PubMed ID: 34002348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
    Jiang Y; Zhao X; Fu J; Wang H
    Front Immunol; 2020; 11():339. PubMed ID: 32226426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of thymic epithelial tumors: molecular understandings and clinical perspectives.
    Ao YQ; Gao J; Wang S; Jiang JH; Deng J; Wang HK; Xu B; Ding JY
    Mol Cancer; 2023 Apr; 22(1):70. PubMed ID: 37055838
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The gut microbiota improves the efficacy of immune-checkpoint inhibitor immunotherapy against tumors: From association to cause and effect.
    Xia L; Zhu X; Wang Y; Lu S
    Cancer Lett; 2024 Aug; 598():217123. PubMed ID: 39033797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A viable remedy for overcoming resistance to anti-PD-1 immunotherapy: Fecal microbiota transplantation.
    Meng Y; Sun J; Zhang G
    Crit Rev Oncol Hematol; 2024 Aug; 200():104403. PubMed ID: 38838927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the regulatory mechanism of intestinal flora based on PD-1 receptor/ligand targeted cancer immunotherapy.
    Gao X; Jiang J
    Front Immunol; 2024; 15():1359029. PubMed ID: 38617841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting the PD-1/PD-L1 pathway in glioblastoma multiforme: Preclinical evidence and clinical interventions.
    Maghrouni A; Givari M; Jalili-Nik M; Mollazadeh H; Bibak B; Sadeghi MM; Afshari AR; Johnston TP; Sahebkar A
    Int Immunopharmacol; 2021 Apr; 93():107403. PubMed ID: 33581502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.
    Routy B; Le Chatelier E; Derosa L; Duong CPM; Alou MT; Daillère R; Fluckiger A; Messaoudene M; Rauber C; Roberti MP; Fidelle M; Flament C; Poirier-Colame V; Opolon P; Klein C; Iribarren K; Mondragón L; Jacquelot N; Qu B; Ferrere G; Clémenson C; Mezquita L; Masip JR; Naltet C; Brosseau S; Kaderbhai C; Richard C; Rizvi H; Levenez F; Galleron N; Quinquis B; Pons N; Ryffel B; Minard-Colin V; Gonin P; Soria JC; Deutsch E; Loriot Y; Ghiringhelli F; Zalcman G; Goldwasser F; Escudier B; Hellmann MD; Eggermont A; Raoult D; Albiges L; Kroemer G; Zitvogel L
    Science; 2018 Jan; 359(6371):91-97. PubMed ID: 29097494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational Approaches Drive Developments in Immune-Oncology Therapies for PD-1/PD-L1 Immune Checkpoint Inhibitors.
    Sobral PS; Luz VCC; Almeida JMGCF; Videira PA; Pereira F
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer.
    Kim E; Ahn H; Park H
    Mamm Genome; 2021 Aug; 32(4):223-231. PubMed ID: 33783613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.